Pneumococcal disease modelling study and cost-effectiveness analysis to assess PCV 1+1 in Thailand
Research areas: Infection, Immunity and Global Health > Asia Pacific Health
Reduced dose schedule for pneumococcal conjugate vaccine (PCV) – will two doses be enough?
Building on a transmission model developed for Fiji, this study aims to calibrate a pneumococcal infectious disease model to support a cost-effectiveness analysis comparing the 1+1 PCV schedule with the standard three-dose schedule.
Building on a transmission model developed for Fiji, this study aims to calibrate a pneumococcal infectious disease model to support a cost-effectiveness analysis comparing the 1+1 PCV schedule with the standard three-dose schedule.
Optimising pneumococcal vaccination schedules in low- and middle-income countries (LMICs)
Recent guidelines from the World Health Organization (WHO) recommend that countries with well-established pneumococcal conjugate vaccine (PCV) programmes may consider switching from a three-dose (3+0) schedule to a two-dose (1+1) schedule, provided they maintain high vaccination coverage and strong monitoring systems.
However, in many low- and middle-income countries (LMICs), limited surveillance infrastructure makes it difficult to support evidence-based policy decisions. As a result, strategies that reduce the cost and complexity of infant PCV programmes, without compromising effectiveness, are critically important.
Study purpose
Building on a transmission model developed for Fiji, this study aims to calibrate a pneumococcal infectious disease model to support a cost-effectiveness analysis comparing the 1+1 PCV schedule with the standard three-dose schedule.
Thailand has been selected as a demonstration site because of its upcoming national PCV rollout using a three-dose schedule. The country is also exploring a potential shift to a 1+1 schedule using PNEUMOSIL®. This policy consideration is linked to a randomised controlled trial of the PNEUMOSIL® 1+1 schedule, led by Thai investigators in collaboration with our team. The trial began in July 2024, following engagement between the Thailand Ministry of Public Health and the Serum Institute of India.
Expanding the impact
Similar modelling work will be conducted in three additional LMICs to support potential transitions from a three-dose to a two-dose PCV schedule. The project will also assess how factors such as vaccination coverage and vaccine-type carriage rates influence model outcomes.
Funders & collaborators
- Gates Foundation
- Department of Foreign Affairs and Trade
- Mahidol University
- London School of Hygiene & Tropical Medicine
- Melbourne School of Population Health
Contact us
Asia-Pacific Heath
Murdoch Children's Research Institute
The Royal Children's Hospital
50 Flemington Road
Parkville VIC 3052
Australia
Email: show email address
Pneumococcal news
Pneumococcal vaccine trial aims to provide more protection to babies
Pneumococcal Vaccine Antibody Assay Platforms
Pneumococcal vaccine study in infants
NHMRC Ideas Grants for neonatal, infectious disease and heart research
Easier access to clinical trials under sweeping changes to medical research
Asia-Pacific Health
Fewer vaccine doses can support pneumococcal immunity in babies
CRE in Pneumococcal Disease Control (CRE-PDC) in the Asia-Pacific — 2021–2025 (archived)
Grant to advance research into severe bacterial pneumonia
Risk factors for carrying pneumonia-causing bacteria revealed
Vaccine reduces likelihood of severe pneumonia
Weak immune system linked to serious bacterial infection in children
Share //
